Metformin induces myeloma cells necrosis and apoptosis and it is considered for therapeutic use

References

• Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet. 2009;374(9686):324–339.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wu Z, Zhang J, et al. Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission. J Transl Med. 2014;12:18.
   PubMed Web of Science ®Google Scholar
• Wu Z, Yu Y, Zhang J, et al. Clustered immature myeloid precursors in intertrabecular region during remission evolve from leukemia stem cell near endosteum and contribute to disease relapse in acute myeloid leukemia. Med Hypotheses. 2013;80(5):624–628.
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen R, Wu L, et al. Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia. Clin Transl Oncol. 2017;19(12):1462–1468.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract. 2020;159:107946.
   PubMed Web of Science ®Google Scholar
• Dulskas A, Patasius A, Linkeviciute-Ulinskiene D, et al. Metformin increases cancer specific survival in colorectal cancer patients-National cohort study. Cancer Epidemiol. 2019;62:101587.
   PubMed Web of Science ®Google Scholar
• Kim YS, Choi EA, Lee JW, et al. Metformin use reduced the overall risk of cancer in diabetic patients: a study based on the Korean NHIS-HEALS cohort. Nutr Metab Cardiovasc Dis. 2020;30(10):1714–1722.
   PubMed Web of Science ®Google Scholar
• Brown JR, Chan DK, Shank JJ, et al. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020;5:e133247.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Barrón F, Padilla MS, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor Receptor-Mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(11):e192553.
   PubMed Web of Science ®Google Scholar
• Han R, Jia Y, Li X, et al. Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance. Transl Lung Cancer Res. 2021;10(3):1277–1291.
   PubMed Web of Science ®Google Scholar
• Fiala O, Ostašov P, Rozsypalová A, et al. Metformin use and the outcome of metastatic renal cell carcinoma treated with sunitinib or pazopanib. CMAR. 2021;13:4077–4086.
   Google Scholar
• Sun S, Cai J, Yang Q, et al. Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis. PLoS One. 2016;11(11):e0166058.
   PubMed Web of Science ®Google Scholar
• Ramos-Peñafiel C, Olarte-Carrillo I, Cerón-Maldonado R, et al. Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene. J Transl Med. 2018;16(1):245.
   PubMedGoogle Scholar
• Fan H, Yu X, Zou Z, et al. Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway. Carcinogenesis. 2019;40(5):669–679.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhu W, Yang B, et al. The co-treatment of metformin with flavone synergistically induces apoptosis through inhibition of PI3K/AKT pathway in breast cancer cells. Oncol Lett. 2018;15(4):5952–5958.
   PubMed Web of Science ®Google Scholar
• Xia C, Chen R, Chen J, et al. Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice. Sci Rep. 2017;7:43373.
   PubMed Web of Science ®Google Scholar
• Li HX, Gao JM, Liang JQ, et al. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin Exp Pharmacol Physiol. 2015;42(6):711–717.
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Chiarini F, Tabellini G, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 2012;26(1):91–100.
   PubMed Web of Science ®Google Scholar
• Shi R, Lin J, Gong Y, et al. The antileukemia effect of metformin in the philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anticancer Drugs. 2015;26(9):913–922.
   PubMed Web of Science ®Google Scholar
• Zi FM, He JS, Li Y, et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 2015;356(2 Pt B):443–453.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J Exp Clin Cancer Res. 2018;37(1):63.
   PubMed Web of Science ®Google Scholar
• Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019;33(11):2695–2709.
   PubMed Web of Science ®Google Scholar
• Chang SH, Luo S, O'Brian KK, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol. 2015;2(1):e30-6–e36.
   PubMed Web of Science ®Google Scholar
• Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111(3):628–636.
   PubMed Web of Science ®Google Scholar
• Scotland S, Saland E, Skuli N, et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia. 2013;27(11):2129–2138.
   PubMed Web of Science ®Google Scholar
• Chomanicova N, Gazova A, Adamickova A, et al. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. Physiol Res. 2021;70(4):501–508.
   PubMed Web of Science ®Google Scholar
• Songthaveesin C, Sa-Nongdej W, Limboonreung T, et al. Combination of metformin and 9-cis retinoic acid increases apoptosis in C6 glioma stem-like cells. Heliyon. 2018;4(5):e00638.
   PubMed Web of Science ®Google Scholar
• Rogalska A, Forma E, Ciesielski P, et al. Effect of metformin on apoptosis induction in ovarian cancer cells. Prz Menopauzalny. 2014;13(3):155–161.
   PubMedGoogle Scholar
• Marini C, Salani B, Massollo M, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle. 2013;12(22):3490–3499.
   PubMed Web of Science ®Google Scholar
• Pateliya B, Burade V, Goswami S. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo. Eur J Pharmacol. 2021;891:173725.
   PubMed Web of Science ®Google Scholar
• Dalva-Aydemir S, Bajpai R, Martinez M, et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res. 2015;21(5):1161–1171.
   PubMed Web of Science ®Google Scholar
• Jagannathan S, Abdel-Malek MA, Malek E, et al. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia. 2015;29(11):2184–2191.
   PubMed Web of Science ®Google Scholar
• Xu S, Zhou T, Doh HM, et al. An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple myeloma. Cancer Res. 2019;79(10):2748–2760.
   PubMed Web of Science ®Google Scholar
• Danziger SA, McConnell M, Gockley J, et al. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the total therapy clinical trials. PLoS Med. 2020;17(11):e1003323.
   PubMed Web of Science ®Google Scholar
• Schueler J, Wider D, Klingner K, et al. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLoS One. 2013;8(11):e79939.
   PubMed Web of Science ®Google Scholar